Chul-Min Ahn

Dr. Chul-Min Ahn


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
SHSung-Jin Hong
Sung-Jin Hong
GMGary S. Mintz
Gary S. Mintz
CAChul-Min Ahn
Chul-Min Ahn
Jung Sun KimJung Sun Kim
Jung Sun Kim
BKByeong‐Keuk Kim
Byeong‐Keuk Kim
MHMyeong-Ki Hong
Myeong-Ki Hong

20 February 2024 in Circulation
Verified
Journal Article
Closed access
SHSung-Jin Hong
Sung-Jin Hong
JLJun-Won Lee
Jun-Won Lee
YSYongsung Suh
Yongsung Suh
KYKyeong Ho Yun
Kyeong Ho Yun
TKTae Soo Kang
Tae Soo Kang
OIon behalf of the T-PASS (Ticagrelor Monotherapy in Patients Treated With New-Generation Drug-Eluting Stents for Acute Coronary Syndrome) Investigators
on behalf of the T-PASS (Ticagrelor Monotherapy in Patients Treated With New-Generation Drug-Eluting Stents for Acute Coronary Syndrome) Investigators
BACKGROUND: Stopping aspirin within 1 month after implantation of a drug-eluting stent for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome. The aim of this study was to investigate whether ticagrelor monotherapy after <1 month of dual antiplatelet therapy (DAPT) is noninferior to 12 months of ticagrelor-based DAPT for adverse cardiovascular and bleeding events in patients with acute coronary syndrome. METHODS: In this randomized, open-label, noninferiority trial, 2850 patients with acute coronary syndrome who underwent drug-eluting stent implantation at 24 centers in South Korea were randomly assigned (1:1) to receive either ticagrelor monotherapy (90 mg twice daily) after <1 month of DAPT (n=1426) or 12 months of ticagrelor-based DAPT (n=1424) between April 24, 2019, and May 31, 2022. The primary end point was the net clinical benefit as a composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, stroke, and major bleeding at 1 year after the index procedure in the intention-to-treat population. Key secondary end points were the individual components of the primary end point. RESULTS: Among 2850 patients who were randomized (mean age, 61 years; 40% ST-segment–elevation myocardial infarction), 2823 (99.0%) completed the trial. Aspirin was discontinued at a median of 16 days (interquartile range, 12–25 days) in the group receiving ticagrelor monotherapy after <1 month of DAPT. The primary end point occurred in 40 patients (2.8%) in the group receiving ticagrelor monotherapy after <1-month DAPT, and in 73 patients (5.2%) in the ticagrelor-based 12-month DAPT group (hazard ratio, 0.54 [95% CI, 0.37–0.80]; P <0.001 for noninferiority; P =0.002 for superiority). This finding was consistent in the per-protocol population as a sensitivity analysis. The occurrence of major bleeding was significantly lower in the ticagrelor monotherapy after <1-month DAPT group compared with the 12-month DAPT group (1.2% versus 3.4%; hazard ratio, 0.35 [95% CI, 0.20–0.61]; P <0.001). CONCLUSIONS: This study provides evidence that stopping aspirin within 1 month for ticagrelor monotherapy is both noninferior and superior to 12-month DAPT for the 1-year composite outcome of death, myocardial infarction, stent thrombosis, stroke, and major bleeding, primarily because of a significant reduction in major bleeding, among patients with acute coronary syndrome receiving drug-eluting stent implantation. Low event rates, which may suggest enrollment of relatively non–high-risk patients, should be considered in interpreting the trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03797651.

20 April 2007 in Heart
Verified
Journal Article
Closed access
PDF file
JHJong-Won Ha
Jong-Won Ha
HLHyun-Chul Lee
Hyun-Chul Lee
EKEun Seok Kang
Eun Seok Kang
CAChul-Min Ahn
Chul-Min Ahn
JKJin-Mi Kim
Jin-Mi Kim
NCNamsik Chung
Namsik Chung
Background: Sublinical myocardial dysfunction occurs in a significant number of patients with type 2 diabetes. Assessment of ventricular long-axis function by measuring mitral annular velocities using tissue Doppler echocardiography (TDE) is thought to provide a more sensitive index of systolic and diastolic function. We hypothesised that augmentation of left ventricular (LV) longitudinal contraction and relaxation during exercise would be blunted in patients with type 2 diabetes. Methods: Mitral annular systolic (S′) and early diastolic (E′) velocities were measured at rest and during supine bicycle exercise (25 W, 3 min increments) in 53 patients (27 male, mean age 53±14 years) with type 2 diabetes and 53 subjects with age and gender-matched control. None had echocardiographic evidence of resting or inducible myocardial ischaemia. Results: There were no significant differences in mitral inflow velocities at rest between the two groups. E′ and S′ at rest were also similar between the groups. However, S′ (7.1±1.3 vs 8.3±1.8 cm/s at 25 W, p = 0.0021; 8.1±1.5 vs 9.1±2.0 cm/s at 50 W, p = 0.026) and E′ (8.5±2.3 vs 9.9±3.1 cm/s at 25 W, p = 0.054; 9.1±2.1 vs 10.9±2.5 cm/s at 50 W, p = 0.0093) during exercise were significantly lower in patients with diabetes compared with controls. Longitudinal systolic and diastolic function reserve indices were significantly lower in patients with diabetes compared with that of controls (systolic index, 0.6±0.70 vs 1.2±1.5 cm/s at 25 W, p = 0.029; 1.2±1.2 vs 2.1±1.6 cm/s at 50 W, p = 0.009; diastolic index, 1.9±1.2 vs 2.5±2.2 cm/s at 25 W, p = 0.07; 2.3±1.3 vs 3.2±2.2 cm/s at 50 W, p = 0.031). Conclusion: In conclusion, unlike resting mitral inflow and annular velocities, changes of systolic and diastolic velocities of the mitral annulus during exercise were significantly reduced in patients with type 2 diabetes compared with the control group. The assessment of LV longitudinal functional reserve with exercise using TDE appears to be helpful in identifying early myocardial dysfunction in patients with type 2 diabetes.

1 May 2021 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
HLHyeok-Hee Lee
Hyeok-Hee Lee
HKHyeon Chang Kim
Hyeon Chang Kim
CAChul-Min Ahn
Chul-Min Ahn
SLSeung-Jun Lee
Seung-Jun Lee
SHSung-Jin Hong
Sung-Jin Hong
YJYangsoo Jang
Yangsoo Jang

1 January 2020 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
SLSeul-Gee Lee
Seul-Gee Lee
JLJun-Won Lee
Jun-Won Lee
JLJung-Jae Lee
Jung-Jae Lee
Jung Sun KimJung Sun Kim
Jung Sun Kim
OLOh-Hyun Lee
Oh-Hyun Lee
YJYangsoo Jang
Yangsoo Jang
Korean Circulation Journal 대한심장학회지 순환기 Lee SG, et al. Korean Circ J. 2019 Aug;50:e53. https://doi.org/10.4070/kcj.2019.0296

1 June 2021 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
JYJeong Hoon Yang
Jeong Hoon Yang
KCKi Hong Choi
Ki Hong Choi
YKYoung-Guk Ko
Young-Guk Ko
CAChul-Min Ahn
Chul-Min Ahn
CYCheol Woong Yu
Cheol Woong Yu
HGHyeon-Cheol Gwon
Hyeon-Cheol Gwon
Background: In the current era of mechanical circulatory support, limited data are available on prognosis of cardiogenic shock (CS) caused by various diseases. We investigated the characteristics and predictors of in-hospital mortality in Korean patients with CS. Methods: The RESCUE study (Retrospective and Prospective Observational Study to Investigate Clinical Outcomes and Efficacy of Left Ventricular Assist Device for Korean Patients With CS) is a multicenter, retrospective, and prospective registry of patients that presented with CS. Between January 2014 and December 2018, 1247 patients with CS were enrolled from 12 major centers in Korea. The primary outcome was in-hospital mortality. Results: In-hospital mortality rate was 33.6%. The main causes of shock were ischemic heart disease (80.7%), dilated cardiomyopathy (6.1%), myocarditis (3.2%), and nonischemic ventricular arrhythmia (2.5%). Vasopressors were used in 1081 patients (86.7%). The most frequently used vasopressor was dopamine (63.4%) followed by norepinephrine (57.3%). An intraaortic balloon pump was used in 314 patients (25.2%) and extracorporeal membrane oxygenator in 496 patients (39.8%). In multivariable analysis, age ≥70years (odds ratio [OR], 2.73 [95% CI, 1.89–3.94], P <0.001), body mass index <25 kg/m 2 (OR, 1.52 [95% CI, 1.08–2.16], P =0.017), cardiac arrest at presentation (OR, 2.16 [95% CI, 1.44–3.23], P 80 (OR, 3.55 [95% CI, 2.54–4.95], P <0.001), requiring continuous renal replacement therapy (OR, 4.14 [95% CI, 2.88–5.95], P <0.001), mechanical ventilator (OR, 3.17 [95% CI, 2.16–4.63], P <0.001), intraaortic balloon pump (OR, 1.55 [95% CI, 1.07–2.24], P =0.020), and extracorporeal membrane oxygenator (OR, 1.85 [95% CI, 1.25–2.76], P =0.002) were independent predictors for in-hospital mortality. Conclusions: The in-hospital mortality of patients with CS remains high despite the high utilization of mechanical circulatory support. Age, low body mass index, cardiac arrest at presentation, amount of vasopressor, and advanced organ failure requiring various support devices were poor prognostic factors for in-hospital mortality. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02985008.